NIH-funded research R01 grant

Investigating how an anti-aging molecule can protect the retina in diabetic patients

Official title: Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina

Funded at University of Texas Med Br Galveston · NIH-11095368 · Data updated 2026-11-12

This study is looking at how a special molecule called Sirt6 might help protect the eyes of people with diabetes from damage that can lead to vision loss, with the goal of finding new ways to keep your eyesight healthy.

More Aging research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Texas Med Br Galveston
NIH-funded
Lab location1 site (Galveston, United States)
Project startMay 1, 2023
Project endApril 30, 2028
Funding year2024
Award (this year)$74,120
NIH project number3R01EY034616-02S1
Project IDNIH-11095368 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are adults with diabetes who are at risk of developing diabetic retinopathy.

Less likely to help

Patients without diabetes or those who have advanced diabetic retinopathy with significant vision loss may not benefit from this research.

What this research studies

This research focuses on diabetic retinopathy, a leading cause of blindness in working-age adults, by exploring the role of the anti-aging molecule Sirt6 in protecting retinal neurons. The study aims to understand the mechanisms behind retinal ganglion cell injury and axonal degeneration in diabetes, which occur early in the disease and contribute to vision loss. By identifying novel strategies to limit this injury, the research seeks to develop new treatments that preserve vision in diabetic patients. The approach includes both animal models and patient studies to gather comprehensive data on the effects of Sirt6 in the retina.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that prevent vision loss in diabetic patients by protecting retinal neurons.

How similar studies have gone: While there have been studies on stress-induced premature senescence in diabetic retinopathy, the specific focus on Sirt6 as a neuroprotective agent is relatively novel.

Where this research is happening

  • University of Texas Med Br Galveston
    Galveston, United States
    Active

Researchers

  • Principal investigator: Zhang, Wenbo — University of Texas Med Br Galveston
  • Study coordinator: Zhang, Wenbo

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.